Floatz logo

Pancrelipase

Exocrine Pancreatic Insufficiency

Anagram Therapeutics, Inc.mixturePhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Exocrine Pancreatic Insufficiency cohort.

Asset / SponsorPhaseRating
Liprotamase
Anthera Pharmaceuticals
Phase 4A
Porcine Pert
Entero Therapeutics
Phase 3BB
Panzytrat
Forest Laboratories
Phase 4BB
Triheptadecanoin
Children's Hospital of Philadelphia
Phase 4BB
ADRULIPASE ALFA
Entero Therapeutics
Phase 2BB

View all 26 →

Same molecule, other indications

Pancrelipase is also rated in:

cystic fibrosisDormant
BB
Indicative ·
69 / 100
View asset →
chronic pancreatitisDormant
BB
Indicative ·
67 / 100
View asset →
exocrine pancreatic insufficiencyDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →